Healthcare Services

Global Neurofibromatosis Type 1 Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Neurofibromatosis Type 1 Market During The Forecast Period 2026–2030?

The neurofibromatosis type 1 market size has seen significant expansion in recent years. This market is projected to grow from $8.83 billion in 2025 to $9.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The historical period’s growth can be attributed to the early identification of nf1 symptoms, the evolution of pain management treatments, an increase in the diagnosis of plexiform neurofibromas, the adoption of surgical tumor removal, and heightened awareness of genetic counseling.

The neurofibromatosis type 1 market is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $13.78 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This growth during the forecast period is fueled by several factors, including an increasing need for targeted nf1 therapies, greater investment in precision oncology, broadening treatment choices for optic glioma, improved access to advanced imaging tools, and the emergence of innovative gene-based treatments. Key developments expected throughout this period involve the rising application of targeted therapy to reduce tumors, a heightened demand for early nf1 genetic testing, an increase in surgical options for tumor removal, the growing use of radiation therapy for optic gliomas, and an elevated emphasis on supportive care and counseling services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp

What Drivers Are Expected To Influence The Neurofibromatosis Type 1 Market During The Forecast Period?

Spontaneous (de novo) mutation is anticipated to drive the future expansion of the neurofibromatosis type 1 (NF1) market. This type of mutation describes a genetic change appearing for the first time in an individual, originating from DNA replication errors or environmental influences, instead of parental inheritance. An increase in spontaneous (de novo) mutations can be linked to factors like advanced parental age, environmental exposures including radiation and chemicals, and inaccuracies in DNA replication during cell division. Neurofibromatosis type 1 (NF1) itself plays a role in these de novo mutations because of the NF1 gene’s high mutation rate, often experiencing significant deletions, insertions, or point mutations during gamete formation, resulting in fresh instances without a prior family history. For example, a report from August 2023 by the US-based peer-reviewed journal Molecular Biology and Evolution indicated that 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring, successfully cleared the Mendelian violation filter. Out of these, 534 probable de novo mutations (DNMs) were found in POR and TVA families, excluding any shared between siblings. Consequently, spontaneous (de novo) mutation is a key factor propelling the expansion of the neurofibromatosis type 1 (NF1) market.

What Market Segments Are Evaluated Within The Neurofibromatosis Type 1 Market?

The neurofibromatosis type 1 market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments

2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants

2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery

3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy

4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling

What Key Trends Are Influencing The Development Of The Neurofibromatosis Type 1 Market?

Leading companies in the neurofibromatosis type 1 (NF1) market are concentrating on introducing innovative products, such as kinase inhibitors, to improve targeted treatment and patient outcomes. A kinase inhibitor is a medication that obstructs the activity of kinases, enzymes responsible for transferring phosphate groups to proteins, thereby regulating various cellular processes. For example, in May 2023, AstraZeneca plc, a UK-based pharmaceutical company, secured approval from China for Koselugo (selumetinib) for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval extends the availability of targeted treatment options for pediatric NF1 patients, enhancing disease management and improving their quality of life. The introduction of Koselugo (selumetinib) in China aligns with the increasing emphasis on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.

Who Are The Top Market Participants Influencing The Neurofibromatosis Type 1 Market?

Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.

Read the full neurofibromatosis type 1 market report here:

https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report

Which Region Is Forecast To Lead The Neurofibromatosis Type 1 Market In Terms Of Market Size?

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurofibromatosis Type 1 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21230&type=smp

Browse Through More Reports Similar to the Global Neurofibromatosis Type 1 Market 2026, By The Business Research Company

Fibromyalgia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Rare Neurological Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Uterine Fibroids Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795